Compare COHN & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COHN | INDP |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.3M | 5.2M |
| IPO Year | 2003 | 2021 |
| Metric | COHN | INDP |
|---|---|---|
| Price | $11.49 | $4.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.8K | ★ 2.5M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | ★ 5537.50 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $275,564,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.33 | ★ N/A |
| Revenue Growth | ★ 246.19 | N/A |
| 52 Week Low | $8.91 | $0.92 |
| 52 Week High | $32.60 | $13.24 |
| Indicator | COHN | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 59.37 |
| Support Level | $10.64 | $1.86 |
| Resistance Level | $16.48 | $5.60 |
| Average True Range (ATR) | 0.59 | 1.07 |
| MACD | 0.30 | 0.18 |
| Stochastic Oscillator | 60.26 | 51.23 |
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.